Endo Health Solutions Inc Stock Downgraded (ENDP)

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

NEW YORK ( TheStreet) -- Endo Health Solutions (Nasdaq: ENDP) has been downgraded by TheStreet Ratings from buy to hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, generally higher debt management risk and disappointing return on equity.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Highlights from the ratings report include:
  • Compared to its closing price of one year ago, ENDP's share price has jumped by 125.53%, exceeding the performance of the broader market during that same time frame. Although ENDP had significant growth over the past year, our hold rating indicates that we do not recommend additional investment in this stock at the current time.
  • Net operating cash flow has increased to $155.44 million or 28.68% when compared to the same quarter last year. The firm also exceeded the industry average cash flow growth rate of -8.08%.
  • The gross profit margin for ENDO HEALTH SOLUTIONS INC is rather high; currently it is at 68.31%. Regardless of ENDP's high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, ENDP's net profit margin of 5.62% is significantly lower than the industry average.
  • The debt-to-equity ratio is very high at 2.39 and currently higher than the industry average, implying increased risk associated with the management of debt levels within the company. Along with the unfavorable debt-to-equity ratio, ENDP maintains a poor quick ratio of 0.77, which illustrates the inability to avoid short-term cash problems.
  • Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Pharmaceuticals industry and the overall market, ENDO HEALTH SOLUTIONS INC's return on equity significantly trails that of both the industry average and the S&P 500.

Endo Health Solutions Inc. provides specialty healthcare solutions in the United States and internationally. Endo Health has a market cap of $7.39 billion and is part of the health care sector and drugs industry. Shares are down 3.6% year to date as of the close of trading on Wednesday.

You can view the full Endo Health Ratings Report or get investment ideas from our investment research center.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.

More from Markets

Credit Suisse Surges After Strong Q1, Record Wealth Management Inflows

Credit Suisse Surges After Strong Q1, Record Wealth Management Inflows

Global Stocks Slide as Yield Pressure, Commodity Surge Prompts Equity Exit

Global Stocks Slide as Yield Pressure, Commodity Surge Prompts Equity Exit

Asian Markets Decline in Morning Trading

Asian Markets Decline in Morning Trading

Verizon Proves Resilient in Sell-Off; Decoding the Facebook Short -- ICYMI

Verizon Proves Resilient in Sell-Off; Decoding the Facebook Short -- ICYMI

Three Big Factors That Rocked the Stock Market Tuesday

Three Big Factors That Rocked the Stock Market Tuesday